BR112018008783A8 - terapia-alvo de câncer - Google Patents

terapia-alvo de câncer

Info

Publication number
BR112018008783A8
BR112018008783A8 BR112018008783A BR112018008783A BR112018008783A8 BR 112018008783 A8 BR112018008783 A8 BR 112018008783A8 BR 112018008783 A BR112018008783 A BR 112018008783A BR 112018008783 A BR112018008783 A BR 112018008783A BR 112018008783 A8 BR112018008783 A8 BR 112018008783A8
Authority
BR
Brazil
Prior art keywords
cancer target
target therapy
antigen
subject
nucleic acid
Prior art date
Application number
BR112018008783A
Other languages
English (en)
Other versions
BR112018008783A2 (pt
Inventor
Todd Schiller John
David Rennert Paul
Lobb Roy
Original Assignee
Aleta Biotherapeutics Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aleta Biotherapeutics Inc, Us Health filed Critical Aleta Biotherapeutics Inc
Publication of BR112018008783A2 publication Critical patent/BR112018008783A2/pt
Publication of BR112018008783A8 publication Critical patent/BR112018008783A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A61K39/00116—Serine proteases, e.g. kallikrein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

algumas formas de realização da presente invenção são dirigidas para métodos que incluem a entrega a um sujeito de uma ácido nucleico que codifica um antigénio, em que o ácido nucleico é entregue através de um veículo de tumor-selectiva ou por injecção intratumoral, e administrar ao indivíduo uma célula imune que expressam um receptor que se liga ao antigénio.
BR112018008783A 2015-10-30 2016-10-28 terapia-alvo de câncer BR112018008783A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562249013P 2015-10-30 2015-10-30
US62/249,013 2015-10-30
PCT/US2016/059452 WO2017075440A1 (en) 2015-10-30 2016-10-28 Targeted cancer therapy

Publications (2)

Publication Number Publication Date
BR112018008783A2 BR112018008783A2 (pt) 2018-10-30
BR112018008783A8 true BR112018008783A8 (pt) 2019-02-26

Family

ID=58631180

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008783A BR112018008783A8 (pt) 2015-10-30 2016-10-28 terapia-alvo de câncer

Country Status (11)

Country Link
US (2) US11207339B2 (pt)
EP (1) EP3368656A4 (pt)
JP (1) JP2018532801A (pt)
KR (1) KR20180095511A (pt)
CN (1) CN108473950A (pt)
AU (1) AU2016343722A1 (pt)
BR (1) BR112018008783A8 (pt)
CA (1) CA3003728A1 (pt)
IL (1) IL259017A (pt)
MX (1) MX2018005468A (pt)
WO (1) WO2017075440A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120266A1 (en) 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
HUE043463T2 (hu) 2013-09-18 2019-08-28 Aura Biosciences Inc Vírusszerû részecske konjugátumok tumorok kezelésére
JP2018532801A (ja) 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法
CN107245500B (zh) * 2017-05-27 2019-05-17 上海优卡迪生物医药科技有限公司 一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用
JP2020524710A (ja) 2017-06-23 2020-08-20 パソヴァックス エルエルシー 免疫応答の抗原特異的リダイレクターとしてのキメラウイルス様粒子およびその使用
EP3664841A1 (en) * 2017-08-11 2020-06-17 City of Hope Oncolytic virus expressing a car t cell target and uses thereof
US20210177921A1 (en) * 2017-11-16 2021-06-17 Virogin Biotech Canada Ltd Targeting moiety-decorated oncolytic viruses
WO2019133847A1 (en) * 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
WO2019200316A1 (en) * 2018-04-13 2019-10-17 Bluebird Bio, Inc. Adoptive cellular therapy
CN110856724B (zh) * 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
CN112930407A (zh) * 2018-11-02 2021-06-08 加利福尼亚大学董事会 使用非人类核酸诊断和治疗癌症的方法
CN109485732B (zh) * 2018-12-20 2021-09-24 四川大学华西医院 基因工程修饰的双靶点嵌合抗原受体及其用途
SG11202106931PA (en) 2018-12-27 2021-07-29 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
CN109943538B (zh) * 2019-03-14 2021-05-25 北京领柯生物科技有限公司 一种肿瘤特异性提升的重组病毒及其改造方案和应用
CN110358734B (zh) 2019-06-13 2020-08-25 首都医科大学宣武医院 以Tcm为主要效应成分的CAR-T制备方法及其应用
WO2021014398A1 (en) 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine
EP4004217A1 (en) * 2019-07-30 2022-06-01 University Health Network T cell receptors and methods of use thereof
EP4004219A4 (en) * 2019-07-30 2023-11-08 University Health Network T-CELL RECEPTORS AND METHODS OF USE THEREOF
JP7429462B2 (ja) * 2019-07-30 2024-02-08 エックスライフエスシー リミテッド Ｓｓｘ２抗原の短いペプチドを識別するｔ細胞受容体
US20230355765A1 (en) * 2019-12-16 2023-11-09 Washington University Chimeric antigen receptor dendritic cells (car-dcs) and methods of making and using same
AU2021364548A1 (en) 2020-10-19 2023-06-08 Verimmune Inc. Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
JP3038339B2 (ja) 1988-05-02 2000-05-08 ザイナクシス・テクノロジーズ・インコーポレーテッド バイオ粒子の表面膜に対してバイオアフェクティング物質を結合する化合物
JP3058686B2 (ja) 1989-08-31 2000-07-04 シティ・オブ・ホープ キメラｄｎａ―ｒｎａ触媒活性配列
DE552178T1 (de) 1990-10-12 1994-02-03 Max Planck Gesellschaft Abgeänderte ribozyme.
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5716824A (en) 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US5783169A (en) 1995-07-26 1998-07-21 Brookhaven Science Associates Llc Rigid bifunctional chelating agents
EP1108724B1 (en) 1996-01-16 2007-09-19 Sirna Therpeutics, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
EP0922105B1 (en) 1996-07-17 2005-12-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Infectious papillomavirus pseudoviral particles
US6180389B1 (en) 1997-01-03 2001-01-30 The Research And Development Institute, Inc. Virion-constrained nanoparticles comprising a plant virion coat protein shell and encapsulated guest molecules
WO1998055607A2 (en) * 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
ES2268787T3 (es) 1997-09-05 2007-03-16 Medimmune, Inc. Metodo in vitro de desmontaje/embalaje de particulas similares a virus (vlp) de papilomavirus.
FR2768749A1 (fr) 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique
WO2000009673A1 (en) 1998-08-13 2000-02-24 Johnson & Johnson Research Pty. Limited Dnazymes and methods for treating hpv-related disorders
US6991795B1 (en) 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
US20050112141A1 (en) 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
US20040146531A1 (en) 1999-09-30 2004-07-29 Active Biotech Ab Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells
WO2001055393A2 (en) * 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
CN1114690C (zh) 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
EP1432799A2 (en) 2001-07-17 2004-06-30 Anne Josephine Milner Silencing of gene expression by sirna
US20030129583A1 (en) 2002-01-08 2003-07-10 Martin William John Therapy of stealth virus associated cancers and other conditions using light
WO2004001019A2 (en) 2002-02-01 2003-12-31 Montana State University Novel nanoparticles and use thereof
AU2003213060A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
JP2003286189A (ja) 2002-03-29 2003-10-07 Japan Science & Technology Corp 中空ナノ粒子を形成するタンパク質に疾患治療用の細胞導入物質を融合させた薬剤
JP4212921B2 (ja) 2002-03-29 2009-01-21 独立行政法人科学技術振興機構 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子
WO2003096990A2 (en) 2002-05-17 2003-11-27 Montana State University Protein cages for the delivery of medical imaging and therapy
BR0311995A (pt) 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
KR100632073B1 (ko) 2002-06-28 2006-10-04 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 시스테인 잔기를 변형한 단백질로 이루어지는 중공 나노입자 및 이를 이용한 약제
JP2004261002A (ja) 2003-01-08 2004-09-24 Tsutomu Suzuki ｓｉＲＮＡの製造方法
EP2184298A1 (en) * 2003-03-14 2010-05-12 Wyeth a Corporation of the State of Delaware Antibodies against human IL-21 receptor and uses therefor
WO2005051431A1 (en) 2003-11-25 2005-06-09 The University Of York Colloidal delivery system for biological therapeutic agents
EP1720990A4 (en) 2004-02-27 2008-04-30 Dow Global Technologies Inc HIGHLY EFFICIENT PEPTIDE PRODUCTION IN PLANT CELLS
JP2008522951A (ja) * 2004-07-19 2008-07-03 ベイラー・カレツジ・オブ・メデイシン サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
US20060216238A1 (en) 2005-02-28 2006-09-28 Marianne Manchester Compositions and methods for targeting or imaging a tissue in a vertebrate subject
ATE546526T1 (de) 2005-05-25 2012-03-15 Univ York Hybrid-interferenz-rna
GB2426687A (en) 2005-05-26 2006-12-06 Jason Kershaw Inter-engaging fasteners
JP5077914B2 (ja) 2005-08-05 2012-11-21 シンジーテック株式会社 電子写真装置用ポリウレタン部材
US20070059746A1 (en) 2005-09-14 2007-03-15 Japan Science And Technology Agency Substance carrier using hollow nanoparticle of hepatitis B virus protein and liposome, and method of introducing substance into cell
WO2008048288A2 (en) 2005-11-09 2008-04-24 Montana State University Novel nanoparticles and use thereof
WO2007126764A2 (en) 2006-03-27 2007-11-08 The Regents Of The University Of California Chemically modified viral capsids as targeted delivery vectors for diagnostic and therapeutic agents
CN100415859C (zh) 2006-07-28 2008-09-03 上海应用技术学院 薰衣草纳米精油的制备方法
KR100962301B1 (ko) 2006-11-03 2010-06-11 재단법인서울대학교산학협력재단 자궁경부암을 위한 치료용 조성물
US20090035389A1 (en) 2007-02-23 2009-02-05 Specigen Inc. Targeted protein cages
US20130136689A1 (en) 2007-06-05 2013-05-30 Christian Rohlff Proteins
SI2145189T1 (sl) 2007-05-08 2016-08-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papilomavirusni psevdovirusi za detekcijo in terapijo tumorjev
EP2262489A2 (en) 2008-02-28 2010-12-22 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Hollow nanoparticles and uses thereof
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
US20120015899A1 (en) 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor
WO2010120266A1 (en) 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof
WO2011039646A2 (en) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Papilloma virus -like particles for targeted gene delivery
US20120207840A1 (en) 2011-02-10 2012-08-16 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment Of Non-Melanoma Skin Cancer
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US20130115247A1 (en) 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US20130116408A1 (en) 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
CN103890177B (zh) 2011-12-01 2016-03-09 开普敦大学 Hpv嵌合颗粒
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
HUE043463T2 (hu) 2013-09-18 2019-08-28 Aura Biosciences Inc Vírusszerû részecske konjugátumok tumorok kezelésére
RU2717984C2 (ru) * 2013-11-21 2020-03-27 ЮСиЭл БИЗНЕС ЛТД Клетка
ES2792849T3 (es) 2014-02-10 2020-11-12 Univ Emory Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
JP2018532801A (ja) 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法

Also Published As

Publication number Publication date
EP3368656A4 (en) 2019-07-17
EP3368656A1 (en) 2018-09-05
CN108473950A (zh) 2018-08-31
JP2018532801A (ja) 2018-11-08
BR112018008783A2 (pt) 2018-10-30
IL259017A (en) 2018-06-28
KR20180095511A (ko) 2018-08-27
US20220313720A1 (en) 2022-10-06
AU2016343722A1 (en) 2018-05-24
MX2018005468A (es) 2018-11-09
CA3003728A1 (en) 2017-05-04
US20180311269A1 (en) 2018-11-01
US11207339B2 (en) 2021-12-28
WO2017075440A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
BR112018008783A8 (pt) terapia-alvo de câncer
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
SV2018005694A (es) Enlazadores de pd1 y/o lag3
BR112018073861A2 (pt) métodos de terapia de genes para doenças e condições relacionadas com a idade
CU20170014A7 (es) Conjugados de fármacos con anticuerpos anti-cdh6
BR112018003186A2 (pt) anticorpos anti-pd-1 e seus métodos de uso
CL2018002532A1 (es) Composición farmacéutica que comprende empagliflozina y sus usos
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
BR112017001183A2 (pt) tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
BR112017018770A2 (pt) redução da tolerância imunológica induzida por pd-l1
UY35399A (es) Conjugados de fármacos con anticuerpos
UY35490A (es) Conjugados de fármacos con anticuerpos
TR201908550T4 (tr) Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
BR112018074990A2 (pt) composição, usos e método para reduzir neutropenia
BR112017010761A2 (pt) tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
BR112016027222A2 (pt) anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
BR112019011065A2 (pt) métodos para determinação da dosagem de células t car
BR112017002369A2 (pt) derivados de diazepana e usos dos mesmos
BR112016027024A2 (pt) polipeptídeos de ligação específica e seus usos
BR112015023886A2 (pt) polipeptídeo, ácido nucleico, composição farmacêutica, e, método
BR112017011556A2 (pt) métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição.
BR112016030172A2 (pt) aptâmeros específicos para tlr-4 e usos dos mesmos
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112015030457A2 (pt) Método para regular positivamente a expressão de antígeno

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]